Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update

Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update

Summary

This 62-page PowerPoint based report gives an important update to the previous year with an expert analysis on how COVID-19 is impacting clinical trials and the potential move toward decentralized clinical trials. Findings are based on a survey conducted with 154 respondents from around the world that belonged to Pharma/Biotech, Government/Academic Institutions, CROs, CMOs, or other contract service providers.

The report includes -
- Study Design and Key Findings.
- Primary Concerns, which include business concerns, clinical trial concerns for decentralized clinical trials and addressing trial disruption.
- Movement Toward Decentralized Trials, including pre and post pandemic decentralized clinical trials use, future movement toward using decentralized clinical trials and cost comparison.
- Challenges Facing Decentralized Trials, which explores the biggest challenges, changes, considerations and risk deviations for decentralized clinical trials.

Scope

- A total of 154 GlobalData Pharma clients and prospects from the around the world participated in the seven-minute survey, which was fielded from August 3, 2021 to September 2, 2021.
- This report includes and is based around industry opinions on COVID-19s impact on clinical trials and the use of decentralized clinical trials.

Reasons to Buy

- Understand companies primary concerns about the COVID-19 pandemic.
- Determine the impact of COVID-19 to date on clinical trials.
- Assess companies future plans to use decentralized clinical trials.
- Track changes to clinical trial strategy and attitudes.

1 Study Design
1.1 Background
1.2 Objectives and Design
1.3 Respondent Mix
1.4 Respondent Profiles
2 Key Findings
3 Primary Business and Clinical Trial Concerns
3.1 Primary Business Concerns
3.2 Primary Clinical Trial Concerns
3.3 Clinical Trial Disruptions
3.4 Addressing Clinical Trial Disruptions
4 Movement Toward Decentralized Trials
3.1 Pre-pandemic Decentralized Trials Use
3.2 Post-pandemic Decentralized Trials Use
3.3 Future Movement Toward Decentralized Clinical Trial Use
3.4 Cost Comparison
4 Challenges Facing Decentralized Trials
4.1 Biggest Challenges
4.2 Biggest Changes
4.3 Biggest Considerations
4.4 Risk Deviations
5 Summary
6 Appendix

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available